EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans

Stephen J Kent iD, Shiyao Li, Thakshila H Amarasena, Arnold Reynaldi, Wen Shi Lee iD, Michael G Leeming, David H O'Connor, Julie Nguyen, Helen E Kent, Frank Caruso iD, Jennifer A Juno, Adam K Wheatley und 2 weitere

ACS Nano · 01.10.2024 · 18 (39) · 27077-27089

DOI: 10.1021/acsnano.4c11652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 19.09.2024. Verfasst von Stephen J Kent und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000,…. Hauptthemen laut MEDLINE: Nanoparticles, COVID-19 Vaccines. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Doherty Institute, Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesCOVID-19 VaccinesHumansSARS-CoV-2mRNA VaccinesLipidsFemaleAdultRNA, MessengerMalePolyethylene GlycolsCOVID-19Middle AgedTissue DistributionLiposomes

Stichwörter der Autor:innen

COVID-19PEGylated lipid nanoparticlebiomolecular coronasimmunoglobulinskinetics of mRNAparticle–immune cell interactions

Substanzen

COVID-19 VaccinesLipid NanoparticlesmRNA VaccinesLipidsRNA, MessengerPolyethylene GlycolsLiposomes

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia.
  • Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria 3000, Australia.
  • School of Science, RMIT University, Melbourne, Victoria 3000, Australia.
  • Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, New South Wales 2052, Australia.
  • Melbourne Mass Spectrometry and Proteomics Facility, The Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
  • Department of Chemical Engineering, The University of Melbourne, Melbourne, Victoria 3000, Australia.

ORCID-Profile: Stephen J Kent, Wen Shi Lee, Frank Caruso, Yi Ju

Förderung

  • National Health and Medical Research Council
  • Doherty Institute
  • Australian Research Council

Zitieren

APA

Kent, S. J., Li, S., Amarasena, T. H., Reynaldi, A., Lee, W. S., Leeming, M. G., O'Connor, D. H., Nguyen, J., Kent, H. E., Caruso, F., Juno, J. A., Wheatley, A. K., Davenport, M. P., & Ju, Y. (2024). Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans. ACS Nano, 18(39), 27077-27089. https://doi.org/10.1021/acsnano.4c11652

Vancouver

Kent SJ, Li S, Amarasena TH, Reynaldi A, Lee WS, Leeming MG, et al. Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans. ACS Nano. 2024;18(39):27077-27089. doi:10.1021/acsnano.4c11652

BibTeX
@article{Kent2024,
  author = {Kent, Stephen J and Li, Shiyao and Amarasena, Thakshila H and Reynaldi, Arnold and Lee, Wen Shi and Leeming, Michael G and O'Connor, David H and Nguyen, Julie and Kent, Helen E and Caruso, Frank and Juno, Jennifer A and Wheatley, Adam K and Davenport, Miles P and Ju, Yi},
  title = {Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {39},
  pages = {27077--27089},
  doi = {10.1021/acsnano.4c11652}
}
Kostenlos starten →